Navigation Links
Angiotech announces results for the fourth quarter ended December 31, 2007
Date:2/14/2008

--------------

Operating (loss)

income (21,717) 63,928 42,211 60,222 43,270 103,492

-------------------------------------------------------------------------

Other income

(expenses):

Foreign exchange

gain(loss) (341) 341 i - 515 (515)i -

Investment and

other income 10,393 (5,422)j 4,971 6,522 (829)k 5,693

Interest expense on

long-term debt (51,748) 2,242 l (49,506) (35,502) 2,019 l (33,483)

Loss on

sale/write-down

of investments (8,157) 8,157 m - (287) 287 n -

Loss extinguishment

of debt - - - (9,297) 9,297 o -

-------------------------------------------------------------------------

(49,853) 5,318 (44,535) (38,049) 10,259 (27,790)

-------------------------------------------------------------------------

Income (loss) from

continuing

operations before

income taxes and

cumulative effect

of change in

accounting (71,570) 69,246 (2,324) 22,173 53,529 75,702

Income tax expense

(recovery) (23,608) 17,589 p (6,019) 10,279 4,933 p 15,212

-------------------------------------------------------------------------

Income (loss) from

continuing

operations before

cumulative effect

of change in

accounting (47,962) 51,657 3,695 11,894 48,596 60,490

-------------------------------------------------------------------------

Net loss from

discontinued

operations, net

of income taxe (11,395) 11,395 - (7,708) 7,708 -

-------------------------------------------------------------------------

Cumulative effect

of change in

accounting - - - 3
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)NEW YORK, Dec. 4 Stemline Therapeutics, Inc. today announced that data from pre-clinical studies of its IL-3R targeting agents, SL-401 and SL-501, in both in vitro and animal models of human chroni
(Date:12/3/2009)DALLAS, Dec. 3 ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a deb
(Date:12/3/2009)WALTHAM, Mass., Dec. 3 Inverness Medical Innovations, Inc. (NYSE: IMA ), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and h
(Date:12/2/2009)MANILA, Philippines, Dec. 2 Spectrum Blue Steel is emerging as one of the fastest growing green energy companies on the planet. Through the efforts of True Green Energy Group and True Green Planet,s
Breaking Biology Technology:Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 3
... Madison, Wis. -- Two years ago, I signed a bud...e state,s history. And on Monday, I signed a budg... our state asked us to do three things with this b...priority, and freeze property taxes. I,m pleased ...ed up to our commitment to Wisconsin families. , ,...
...The Wisconsin Alumni Research Foundation has lic...Chemicon to commercialize research products using...ny Serologicals announced Tuesday. , ,Chemicon w...of stem cell technologies, which were developed an...dison . , ,Jeff Linton, president of Chemicon, sa...
... - Firstlogic, Inc ., a provider of enterprise i...that Crate and Barrel housewares retailer has de...anage the data quality in its new customer managem...stlogic,s software suite to achieve data quality i...nels where customer and product data flows.The sys...
Other Biology Technology:A budget that moves Wisconsin forward 2A budget that moves Wisconsin forward 3A budget that moves Wisconsin forward 4WARF signs stem cell agreement with California firm 2
(Date:12/3/2009)The extinction of plant and animal species can be likened to emptying a museum of its collection, or dumping a cabinet full of potential medicines into the trash, or replacing every local cuisine with
(Date:12/3/2009)ALBUQUERQUE, N.M. Most scientists believe that staph infections are caused by many bacterial cells that signal each other to emit toxins. The signaling process is called quorum sensing because many b
(Date:12/3/2009)Forest dwellers must be included in the design of the upcoming forest deal at Copenhagen in order to avoid a humanitarian crisis, according to a scientist at the University of Leeds. , Writing today
Breaking Biology News(10 mins):Species down, disease up 2Species down, disease up 3Species down, disease up 4Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 3Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Xanodyne Announces New President CEO and Completes 2438 Million Equity Financing 47880 1Xanodyne Announces New President CEO and Completes 2438 Million Equity Financing 47880 2In Both the U S and Mexico we Must Advance not Retreat From Strategic Government Goals Regarding Drug Addiction and Drug Related Crime Says Narcono 47878 1In Both the U S and Mexico we Must Advance not Retreat From Strategic Government Goals Regarding Drug Addiction and Drug Related Crime Says Narcono 47878 2Cardiogenesis Announces Presentation of its PHOENIX 28R 29 Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally In 4536 1Cardiogenesis Announces Presentation of its PHOENIX 28R 29 Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally In 4536 2Cardiogenesis Announces Presentation of its PHOENIX 28R 29 Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally In 4536 3
...researchers have developed a computer modeling app... antibodies, molecules key to the immune system. T...body that will improve its effectiveness. , The ...rsion of cetuximab, a drug commonly used to treat ...0 times greater affinity than the original molecul...
... bioMETRX, Inc. (OTC,Bulletin Board: BMRX) a lead... today announced that it has acquired a patent tha...ecure portable locks. The company believes that t.... For many years, consumers have been using portab...to secure personal belongings in lockers,and stora...
..., Sept. 10 ,Communication Intelligence Corporation...lier of electronic signature solutions for busines... the recognized leader in biometric,signature veri...el Betts to,the CIC Board of Directors. Mr. Betts...and,financial services industries and holds the FL...
Other Biology News:MIT model could improve some drugs' effectiveness 2MIT model could improve some drugs' effectiveness 3bioMETRX, Inc. Acquires Patent for Biometric Padlock 2Michael A. Betts, Seasoned Financial Services Executive, Joins CIC Board of Directors 2Michael A. Betts, Seasoned Financial Services Executive, Joins CIC Board of Directors 3
GIBCO Dulbecco's Phosphate-Buffered Saline (D-PBS) (1X) liquid from Invitrogen
(Miller's LB Broth Base) Luria Broth Base powder from Invitrogen
Rat TNF-alpha ELISA Kit, OptEIA from BD Biosciences Pharmingen
LB Broth Base powder (Lennox L Broth Base) from Invitrogen
Biology Products: